To stimulate cognition and memory by selectively

( PRX-3140 may potentially slow the progression of the disease )

PleaseHelpSupport Alzheimer's Research Today!
Your Alzheimer's donation will help billionslive without it. Donate online now

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. PRX-3140 - an orally-bioavailable Alzheimer’s treatment - is in Phase 2 clinical studies. Nanotherapeutics also acquired the U.S. and foreign patent estates covering each clinical program.

PRX-3140 is intended to stimulate cognition and memory by selectively activating the 5-HT4 G-protein coupled receptor in the brain to produce and release acetylcholine, a neurotransmitter that plays a role in learning and memory. As Alzheimer’s disease progresses, acetylcholine production declines, and brain levels of this critical neurotransmitter decline also. PRX-3140 may potentially slow the progression of the disease with fewer and less severe side effects than certain current Alzheimer drugs. A randomized, double-blind, placebo-controlled Phase 2a clinical trial was completed to assess the effects of PRX-3140 following two weeks of treatment as monotherapy and separately in combination with donepezil (Aricept®) in patients with mild Alzheimer's disease. In this study, PRX-3140 appeared to be well tolerated alone and in combination with Aricept® with no serious drug-related adverse events reported. In October, 2009, the FDA permitted a Physician-Sponsored IND and continuation of the fourth six-month open label extension of PRX-3140.

Alzheimer’s disease is the most common form of dementia, affecting more than five million Americans and over nine million worldwide. The National Institute of Aging estimates that about five percent of the population aged 65-74 and as many as 50% of the US population over 85 have the disease. The global market is projected to grow from $4 billion in 2006 to over $5 billion in 2010. The disease is currently incurable and manifests as progressive memory loss, confusion, and ultimately loss of control of physical and mental functions leading to death.

Nanotherapeutics, Inc. is a privately held biopharmaceutical company. Its product pipeline includes, an FDA-approved injectable biologic product (OrigenTM DBM, marketing partner Orthofix), an FDA filed product (NanoFUSETM bone graft), and other products in clinical trials including NanoDOX® and NanoBUPTM. The Company also has in-house GMP manufacturing to support additional products. The 10-year old company employs several platform technologies to manipulate and enhance the properties of drugs, has an experienced management and development team, and a pipeline of clinical and pre-clinical pharmaceutical and biologic products. For more information, visit the Company website at www.nanotherapeutics.com. ...http://www.newswise.com

Aker krill injunction appeal dismissed by German court

A local district court has ruled that Norwegian krill supplier, Aker Biomarine, misrepresented its European Union novel foods status at the Food Ingredients Europe (FIE) trade show in Frankfurt in mid-November. ... ...http://www.nutraingredients.com/

Беларусь ТВ

Posted YVN